Pamela Farrell

University of Calgary — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index218citations26works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(11), Cancer-related Molecular Pathways(8), Cancer, Hypoxia, and Metabolism(8), Liver physiology and pathology(5), Cancer Mechanisms and Therapy(5)

Publications26 total

“Food Brings People Together”
Canadian Food Studies / La Revue canadienne des études sur l alimentation·2025Open Access
Supplementary Figure Legends from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
2023Open Access
Data from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
2023Open Access
Data from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 1 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 2 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
2023Open Access
Supplementary Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
2023Open Access
Supplementary Figure 1 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure Legends from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 2 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Getting Your Work Published: Advice for New and Developing Scholars
SHILAP Revista de lepidopterología·2022Open Access
Conceptualizing Food Literacy: A Literature Review
SHILAP Revista de lepidopterología·2021· 4 citedOpen Access
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors
Journal of Pharmacology and Experimental Therapeutics·2019· 10 citedOpen Access
MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes
Journal of Biological Chemistry·2019· 13 citedOpen Access
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
Molecular Cancer Therapeutics·2017· 12 cited
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
Bioorganic & Medicinal Chemistry Letters·2016· 12 citedOpen Access
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
Bioorganic & Medicinal Chemistry Letters·2016· 60 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Ron de Jong(18), Jennifer Matuszkiewicz(17), Deepika Balakrishna(17), Charles E. Grimshaw(11), Petro Halkowycz(11), Bheema Paraselli(11), Lilly Zhang(10), Robyn Fabrey(10), Bumsup Lee(10), Bi‐Ching Sang(10), Seigo Ishino(10), Toshiyuki Nomura(10), Mika Teratani(10), Yoshikazu Ohta(10), Lihong Shi(8), Takashi Hoshino(8), Sarah Elliott(8), Takashi Satou(8), J. David Lawson(6), Shweta Pandya(5)